重组人脑利钠肽对硝普钠疗效欠佳扩张型心肌病慢性心力衰竭急性加重患者的临床观察
打开文本图片集
【摘要】 目的 观察重组人脑利钠肽（rhBNP）治疗硝普钠疗效欠佳扩张型心肌病慢性心力衰竭急性加重的临床效果。方法 20例扩张型心肌病慢性心力衰竭急性加重硝普钠治疗效果欠佳的患者为研究对象， 观察重组人脑利钠肽治疗前后患者临床症状、体征及心功能改善情况， 对临床效果进行评价。结果 治疗后， 心率（HR）、脑利钠肽（BNP）较治疗前明显降低， 差异有统计学意义（P<0.001）；左室射血分数（LVEF）、左室舒张末期内径（LVEDd）均较治疗前有明显改善， 差异有统计学意义（P<0.001）。结论 重组人脑利钠肽对于治疗硝普钠疗效欠佳扩张型心肌病慢性心力衰竭急性加重具有较好的临床作用且不良反应少， 可在临床推广应用。
【关键词】 重组人脑利钠肽；硝普钠；扩张型心肌病；心力衰竭
【Abstract】 Objective To observe clinical effect of recombinant human brain natriuretic peptide （rhBNP） for dilated cardiomyopathy chronic heart failure acute exacerbation patients with poor effect by sodium nitroprusside. Methods There were 20 dilated cardiomyopathy chronic heart failure acute exacerbation patients with poor effect by sodium nitroprusside as study subjects. Their improvements in clinical symptoms， signs， and cardiac function were observed before and after recombinant human brain natriuretic peptide treatment. Their clinical effects were evaluated. Results After treatment， heart rate （HR） and brain natriuretic peptide （BNP） were much lower than those before treatment， and their difference had statistical significance （P<0.001）. Left ventricular ejection fraction （LVEF） and left ventricular end-diastolic dimension （LVEDd） were all improved after treatment， and their difference had statistical significance （P<0.001）. Conclusion Recombinant human brain natriuretic peptide ...
|
== 试读已结束，如需继续阅读敬请充值会员 ==
|
|
本站文章均为原创投稿，仅供下载参考，付费用户可查看完整且有格式内容！
(费用标准：38元/2月，98元/2年，微信支付秒开通！) |
| 升级为会员即可查阅全文 。如需要查阅全文，请 免费注册 或 登录会员 |
|
